Overview

Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Our previous collaborative studies has developed a molecular diagnosis tool, which is characterized with a prediction model consisting single nucleotide polymorphisms (SNPs), for assessing the efficacy of interferon combined therapy for chronic hepatitis C (CHC) patients prior to treatment. Aims of this project: 1. To analyze and validate the gene expression profiling dependent of treatment response to peg-interferon-α plus ribavirin combination therapy in CHC genotype-1 patients. 2. To select the candidate genes and establish a monitoring model assessing the efficacy of interferon treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Kaohsiung Medical University Chung-Ho Memorial Hospital
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin